← All trials
NCT05234684
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 2, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 30, 2025
- First posted
- Feb 10, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing InnoCare Pharma Tech Co., Ltd.Lead sponsor
- Shanghai Ruijin Hospital NorthOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.